GSK

GSK plc has taken a significant step in advancing treatment options for relapsed or refractory multiple myeloma by submitting a Biologics License Application (BLA)...

GSK plc has successfully secured approval from Japan's Ministry of Health, Labor and Welfare (MHLW) to extend the use of its respiratory syncytial virus...

GSK plc unveiled promising results from its Phase III GLISTEN trial, showcasing linerixibat's effectiveness in alleviating chronic itching among individuals with primary biliary cholangitis...

Key TakeawaysNovartis ranks first, with GSK following closely, yet overall progress in access to essential medicines remains stagnant. Only 43% of clinical trials...

Key TakeawaysGSK's acquisition solidifies its position in the autoimmune disease treatment space.  CMG1A46 offers a novel approach targeting both CD19 and CD20, potentially...

GSK has unveiled groundbreaking data on its Arexvy vaccine, offering hope for expanding protection against respiratory syncytial virus (RSV) to a wider demographic. This...

Key TakeawaysGepotidacin, a novel oral antibiotic, has been accepted by the FDA for priority review, potentially becoming the first new treatment for uncomplicated...

Key TakeawaysGSK and the University of Cambridge announce a five-year partnership to develop therapies for kidney and respiratory diseases using immunology and AI. ...

Key TakeawaysGSK and ViiV Healthcare will present 60 abstracts at IDWeek 2024, showcasing innovations in vaccines and therapeutics, including solutions for HIV, antimicrobial...

Key TakeawaysGSK's depemokimab, administered biannually, demonstrated significant reduction in nasal polyp size and nasal obstruction in patients with chronic rhinosinusitis with nasal polyps...

Key TakeawaysA packaging issue affecting the sterility of needle soft packs included with Infanrix Hexa pediatric vaccines has been identified. The defect involves...

Key TakeawaysRespiratory syncytial virus poses a significant health risk for older adults, and GSK's Arexvy vaccine has shown promising efficacy of 62.9% against...

Key TakeawaysHIV epidemic prevention efforts are being strengthened as ViiV Healthcare triples its supply of long-acting cabotegravir for PrEP to low- and middle-income...

Key TakeawaysGSK’s Menveo (MenACWY) receives a positive opinion for a fully liquid, single-vial presentation from the EMA. If approved, this version will simplify...

Key TakeawaysThe next round is expected to target COPD drugs like GSK's Breo Ellipta and Trelegy Ellipta. ICER is preparing a special report...